---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060813"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:48:33.404881+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics updates pipeline timelines; cash $123M, runway into 2H2024

## Summary
- KORSUVA injection US launch ongoing; Japan approval expected 2H2023; EU launch 2H2022.
- Oral difelikefalin Phase 3 for non-dialysis CKD-aP (KICK1/2) topline data 2H2024.
- Phase 3 for atopic dermatitis (KIND1/2) internal readout 4Q2023, topline 1H2025.
- Phase 2/3 for notalgia paresthetica (KOURAGE1) internal readout 2H2024.
- Cash $123M as of Mar 31, 2023; no debt; cash runway into 2H2024.

## SEC filing metadata
- accession: 0001104659-23-060813
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923060813/0001104659-23-060813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923060813/tm2315680d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060813
- JSON: https://secwatch.observer/filing/0001104659-23-060813.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.